SofWave Medical Ltd. (SOFWF)
| Market Cap | 447.58M +36.7% |
| Revenue (ttm) | 104.35M +50.2% |
| Net Income | 8.85M |
| EPS | 0.21 |
| Shares Out | n/a |
| PE Ratio | 55.12 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 11.44 |
| Previous Close | 11.44 |
| Day's Range | 11.44 - 11.44 |
| 52-Week Range | 9.14 - 16.49 |
| Beta | 0.71 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 11, 2026 |
About SofWave Medical
SofWave Medical Ltd. engages in the development, production, marketing, and distribution of non-invasive medical technology for skin firming and rejuvenation, tissue renewal, treatment of muscle, aging, and other physiological change in Israel, the United States, Europe, Southeast Asia, the Middle East, and internationally. The company offers an ultrasound technology that induces coagulation and subsequent revitalization for regenerated skin under the SUPERB brand; and non-invasive muscle toning technology under the Pure Impact VIP brand. It se... [Read more]
Financial Performance
Financial StatementsNews
SofWave Medical Earnings release: Q3 2026
SofWave Medical released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
SofWave Medical Quarterly report: Q3 2026
SofWave Medical has published its Q3 2026 quarterly earnings report on November 3, 2026.
SofWave Medical Slides: Q3 2026
SofWave Medical has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
SofWave Medical Transcript: Jefferies Private MedTech Virtual Summit
Q2 2026 revenue rose 43% YoY to $29.96M, while usage fees grew 52% to $13.9M. China launch is slated for Q4 2026, and management expects 2027 to be an exceptional commercial year for Pure Impact VIP.
SofWave Medical Earnings Call Transcript: Q2 2026
Q2 revenue hit a record $29.96M, up 43% YoY, with 76.5% gross margin and adjusted operating income up 41%. Usage fees and utilization accelerated; H2 priorities include productivity, next-generation development, and potential China commercialization subject to approval.
SofWave Medical Earnings release: Q2 2026
SofWave Medical released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
SofWave Medical Quarterly report: Q2 2026
SofWave Medical has published its Q2 2026 quarterly earnings report on August 11, 2026.
SofWave Medical Slides: Q2 2026
SofWave Medical has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 11, 2026.
SofWave Medical Transcript: Planet MicroCap Las Vegas 2026
Strong demand for non-invasive skin rejuvenation and a unique business model have driven rapid growth, with over 40% of revenue now recurring and nearly 100% gross margin on consumables. Geographic expansion, new indications, and a robust IP portfolio position the company for continued high double-digit growth.
Sofwave Medical Reports First Quarter Fiscal 2026 Financial Results and Business Highlights
SAN CLEMENTE, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, report...
SofWave Medical Earnings release: Q1 2026
SofWave Medical released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
SofWave Medical Quarterly report: Q1 2026
SofWave Medical has published its Q1 2026 quarterly earnings report on May 5, 2026.
SofWave Medical Slides: Q1 2026
SofWave Medical has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
SofWave Medical Earnings Call Transcript: Q4 2025
Revenue grew 58% year-over-year in Q4 and 47% for the full year, with ongoing usage fees now 43% of total revenue. Achieved IFRS profitability, strong gross margins, and expanding global footprint, driven by demand for regenerative, non-invasive treatments.
SofWave Medical Earnings release: Q4 2025
SofWave Medical released its Q4 2025 earnings on March 17, 2026, summarizing the period's financial results.
SofWave Medical Slides: Q4 2025
SofWave Medical has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 17, 2026.
SofWave Medical Annual report: Q4 2025
SofWave Medical has published its Q4 2025 annual report on March 17, 2026.
SofWave Medical Transcript: CG MedTech, Diagnostics and Digital Health & Services Forum
Record Q3 revenue and strong profitability were driven by recurring virtual consumable sales and global expansion. Innovative non-invasive technology, high customer satisfaction, and a growing GLP-1 patient segment are fueling demand and supporting a robust financial outlook.
SofWave Medical Transcript: Jefferies London Healthcare Conference 2025
Exceptional revenue growth and profitability have been achieved, driven by proprietary technology, recurring revenue, and global expansion. Demand for non-invasive treatments is rising, with strong brand awareness and high provider satisfaction supporting continued growth.
SofWave Medical Transcript: Stifel 2025 Healthcare Conference
Record revenue growth, strong recurring revenue from virtual consumables, and high profitability mark recent performance. Product innovation and regulatory wins, especially in Japan, support global expansion, while GLP-1 trends drive demand for skin tightening and muscle toning.